In this review, the authors outline the use of allogeneic hematopoietic cell transplantation (HCT) to treat multiple myeloma (MM), noting that allogeneic HCT should be strongly considered only for high-risk MM patients as part of their initial course of therapy or in first chemotherapy-sensitive relapse within a clinical trial. They note that despite progress in survival with the availability of novel agents, an overwhelming majority of patients with multiple myeloma (MM) relapse, and that allogeneic HCT is a potentially curative option that has several advantages including a tumor-free graft, and the potential for sustained immune-mediated disease control. The authors note that allogeneic HCT can have a high treatment-related mortality (TRM), but that “newer preparative regimens, planned maintenance strategies and improvements in supportive care have led to a decline in TRM and better survival in recent years.”
Dhakal B, et al. Bone Marrow Transplant